- Home
- LITB vs BCAB Comparison
LITB vs BCAB Comparison
Compare LITB & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LITB
- BCAB
- Stock Information
- Founded
- LITB 2007
- BCAB 2007
- Country
- LITB Singapore
- BCAB United States
- Employees
- LITB N/A
- BCAB N/A
- Industry
- LITB Catalog/Specialty Distribution
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- LITB Consumer Discretionary
- BCAB Health Care
- Exchange
- LITB Nasdaq
- BCAB Nasdaq
- Market Cap
- LITB 21.1M
- BCAB 22.3M
- IPO Year
- LITB N/A
- BCAB 2020
- Fundamental
- Price
- LITB $1.31
- BCAB $0.38
- Analyst Decision
- LITB
- BCAB Buy
- Analyst Count
- LITB 0
- BCAB 2
- Target Price
- LITB N/A
- BCAB $1.00
- AVG Volume (30 Days)
- LITB 10.8K
- BCAB 541.7K
- Earning Date
- LITB 08-01-2025
- BCAB 08-07-2025
- Dividend Yield
- LITB N/A
- BCAB N/A
- EPS Growth
- LITB N/A
- BCAB N/A
- EPS
- LITB 0.08
- BCAB N/A
- Revenue
- LITB $231,136,000.00
- BCAB $11,000,000.00
- Revenue This Year
- LITB N/A
- BCAB N/A
- Revenue Next Year
- LITB N/A
- BCAB N/A
- P/E Ratio
- LITB $16.67
- BCAB N/A
- Revenue Growth
- LITB N/A
- BCAB N/A
- 52 Week Low
- LITB $0.91
- BCAB $0.24
- 52 Week High
- LITB $4.98
- BCAB $2.53
- Technical
- Relative Strength Index (RSI)
- LITB 57.98
- BCAB 44.12
- Support Level
- LITB $1.22
- BCAB $0.36
- Resistance Level
- LITB $1.34
- BCAB $0.42
- Average True Range (ATR)
- LITB 0.08
- BCAB 0.03
- MACD
- LITB 0.02
- BCAB -0.00
- Stochastic Oscillator
- LITB 82.76
- BCAB 29.75
About LITB LightInTheBox Holding Co. Ltd.
LightInTheBox Holding Co Ltd is an online retail company delivering products directly to consumers across the world. It provides apparel products including customized, special occasion and fast fashion apparel products; and other general merchandise products, such as accessories and gadgets, home and garden products, electronics and communication devices, and other products. The company operates in two segments: Product sales which consisted of online retailing of consumer products and sales to third-party sellers, and Services which consisted of provision of logistic services to companies and to individual customers. It derives maximum revenue from Product Sales. Geographically, it operates in Europe which is the key revenue driver, North America, and other countries.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.